title: Early changes in insulin secretion and action induced by high-fat diet are related to a decreased sympathetic tone.
abstract: To evaluate the relationship between the development of obesity, nervous system activity, and insulin secretion and action, we tested the effect of a 2-mo high-fat diet in rats (HF rats) on glucose tolerance, glucose-induced insulin secretion (GIIS), and glucose turnover rate compared with chow-fed rats (C rats). Moreover, we measured pancreatic and hepatic norepinephrine (NE) turnover, as assessment of sympathetic tone, and performed hypothalamic microdialysis to quantify extracellular NE turnover. Baseline plasma triglyceride, free fatty acid, insulin, and glucose concentrations were similar in both groups. After 2 days of diet, GIIS was elevated more in HF than in C rats, whereas plasma glucose time course was similar. There was a significant increase in basal pancreatic NE level of HF rats, and a twofold decrease in the fractional turnover constant was observed, indicating a change in sympathetic tone. In ventromedian hypothalamus of HF rats, the decrease in NE extracellular concentration after a glucose challenge was lower compared with C rats, suggesting changes in overall activity. After 7 days, insulin hypersecretion persisted, and glucose intolerance appeared. Later (2 mo), there was no longer insulin hypersecretion, whereas glucose intolerance worsened. At all times, HF rats also displayed hepatic insulin resistance. On day 2 of HF diet, GIIS returned to normal after treatment with oxymetazoline, an alpha(2A)-adrenoreceptor agonist, thus suggesting the involvement of a low sympathetic tone in insulin hypersecretion in response to glucose in HF rats. In conclusion, the HF diet rapidly results in an increased GIIS, at least in part related to a decreased sympathetic tone, which can be the first step of a cascade of events leading to impaired glucose homeostasis.
authors.affiliation: Laboratoire de Physiopathologie de la Nutrition, Centre National de la Recherche Scientifique, UMR 7059, Université Paris 7, Paris, France. cruciani@paris7.jussieu.fr
authors.forename: C
authors.initials: C
authors.lastname: Cruciani-Guglielmacci
authors.forename: M
authors.initials: M
authors.lastname: Vincent-Lamon
authors.forename: C
authors.initials: C
authors.lastname: Rouch
authors.forename: M
authors.initials: M
authors.lastname: Orosco
authors.forename: A
authors.initials: A
authors.lastname: Ktorza
authors.forename: C
authors.initials: C
authors.lastname: Magnan
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D004041:Dietary Fats / Q000494:pharmacology*; D004435:Eating; D006943:Hyperglycemia / Q000503:physiopathology; D006946:Hyperinsulinism / Q000503:physiopathology; D007031:Hypothalamus / Q000502:physiology; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D008099:Liver / Q000502:physiology; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010109:Oxymetazoline / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*; D013566:Sympathomimetics / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D004041:Dietary Fats; D007328:Insulin; D013566:Sympathomimetics; D010109:Oxymetazoline; D009638:Norepinephrine